686 related articles for article (PubMed ID: 10727983)
41. [Contribution of monoclonal antibody HMB45 in the histopathologic diagnosis of melanoma].
Pluot M; Joundi A; Grosshans E
Ann Dermatol Venereol; 1990; 117(10):691-9. PubMed ID: 1705764
[TBL] [Abstract][Full Text] [Related]
42. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
43. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
Touab M; Arumi-Uría M; Barranco C; Bassols A
Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
45. Immunostaining for MART-1 in the interpretation of problematic intra-epidermal pigmented lesions.
Wiltz KL; Qureshi H; Patterson JW; Mayes DC; Wick MR
J Cutan Pathol; 2007 Aug; 34(8):601-5. PubMed ID: 17640229
[TBL] [Abstract][Full Text] [Related]
46. Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma.
Zhuang L; Scolyer RA; Lee CS; McCarthy SW; Cooper WA; Zhang XD; Thompson JF; Hersey P
Histopathology; 2009 Mar; 54(4):462-70. PubMed ID: 19309398
[TBL] [Abstract][Full Text] [Related]
47. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
48. Molecular analysis of melanoma precursor lesions.
Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
[TBL] [Abstract][Full Text] [Related]
49. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
50. [Melanocytic nevi].
Crickx B
Rev Prat; 1999 Apr; 49(8):829-32. PubMed ID: 10337194
[TBL] [Abstract][Full Text] [Related]
51. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
52. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
53. Pitfalls in the evaluation of melanocytic lesions.
Brenn T
Histopathology; 2012 Apr; 60(5):690-705. PubMed ID: 22176022
[TBL] [Abstract][Full Text] [Related]
54. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma.
Sanki A; Li W; Colman M; Karim RZ; Thompson JF; Scolyer RA
Pathology; 2007 Dec; 39(6):551-7. PubMed ID: 18027257
[TBL] [Abstract][Full Text] [Related]
55. The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers.
Quiohilag K; Caie P; Oniscu A; Brenn T; Harrison D
Virchows Arch; 2020 Jul; 477(1):121-130. PubMed ID: 32388720
[TBL] [Abstract][Full Text] [Related]
56. Moesin and CD44 expression in cutaneous melanocytic tumours.
Ichikawa T; Masumoto J; Kaneko M; Saida T; Sagara J; Taniguchi S
Br J Dermatol; 1998 May; 138(5):763-8. PubMed ID: 9666819
[TBL] [Abstract][Full Text] [Related]
57. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
58. Systematic search for the best gene expression markers for melanoma micrometastasis detection.
Soikkeli J; Lukk M; Nummela P; Virolainen S; Jahkola T; Katainen R; Harju L; Ukkonen E; Saksela O; Hölttä E
J Pathol; 2007 Oct; 213(2):180-9. PubMed ID: 17891747
[TBL] [Abstract][Full Text] [Related]
59. Morphometry of melanocytic skin lesions--verifications or vexations? A review of a group experience.
Williams RA
Pathologica; 1998 Apr; 90(2):183-5. PubMed ID: 9619064
[No Abstract] [Full Text] [Related]
60. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
Kuźbicki L; Gajo B; Chwirot BW
Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]